Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preliminary efficacy study of sodium oligomannate capsule in early- and mid-stage Parkinson's disease
ChiCTR2100042680Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2020
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sodium oligomannate in Parkinson's disease (PD) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Unified Parkinson's Disease Rating Scale and Intestinal flora diversity and abundance. Started Aug 2020; status: recruiting.
02
Drugs
sodium oligomannate
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ChiCTR2100042680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042680.